In today's episode, Dr. Alok Patel (@alokpatelmd) & Eva Johnson cover the FDA clearance of Motivista as the first prescription app for negative symptoms of schizophrenia. They break down the 16 week CONVOKE trial and what a 2.6 point edge over a control app means for stable patients on antipsychotics. They also review new ACP guidance placing menopausal hormone therapy first for hot flashes and night sweats, with second and third line options. Plus: they discuss early feasibility data on a medical AI chatbot for pre visit histories, new federal recommendations on concentrated kratom products, and more.
Coverage Timeline:
(00:00) Intro
(01:08) Schizophrenia App Cleared
(03:50) Hot Flashes Guidance
(04:47) Dogs & Sleep Study
(06:51) AI In Urgent Care
(08:37) Awards & Dahlias
Have a story, think we missed something, want to say hi, or curious to learn about the Medlines team? Visit www.medlinespod.com or email medlines@human-content.com.
Sources & Media Attributions for Today's Episode Available At: www.medlinespod.com/sources
Podden och tillhörande omslagsbild på den här sidan tillhör
Human Content, Inc.. Innehållet i podden är skapat av Human Content, Inc. och inte av,
eller tillsammans med, Poddtoppen.
